FTSE 100 edges higher as UK approves AstraZeneca's COVID-19 vaccine

Published 30/12/2020, 09:13
Updated 30/12/2020, 09:18
© Reuters.

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)
* FTSE 100 up 0.1%, FTSE 250 adds 0.1%

Dec 30 (Reuters) - London's FTSE 100 inched higher on
Wednesday after Britain approved a coronavirus vaccine developed
by AstraZeneca and Oxford University, although surging COVID-19
cases in the country kept investors cautious.
The blue-chip FTSE 100 .FTSE rose 0.1% by 0803 GMT,
struggling to break past a fresh 10-month high hit in the
previous session.
Drugmaker AstraZeneca AZN.L rose 1.6%, giving the biggest
boost to the index, after the company said it is working with
the government to begin vaccinations early next year.
The regulatory approval is a welcome boost for AstraZeneca
and the Oxford team, which has been accused of lack of clarity
about the results from late-stage trials. The mid-cap FTSE 250 index .FTMC , considered a barometer
of Brexit sentiment, rose 0.1%. British lawmakers will vote on
the UK-EU trade deal in parliament later in the day.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.